Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it plans to sell its wholly owned subsidiary, BioServe Biotechnologies, to Reprocell for up to $1.9 million.

Under the terms of the acquisition, Reprocell , a Japanese stem cell research company, will pay Cancer Genetics $1.6 million upfront. The remaining balance will be payable about six months after the deal's closing, subject to BioServe's revenues for a four-month period after closing being equivalent to the same four-month period in 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.